Shikiar Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Shikiar Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,045	Closed	-$219K	–	114
2016 Q4	$219K	Sell	6,045 -15,325	-72%	-$612K	0.1%	95
2016 Q3	$983K	Buy	21,370 +4,475	+26%	+$233K	0.44%	45
2016 Q2	$849K	Buy	16,895 +11,095	+191%	+$591K	0.38%	43
2016 Q1	$310K	Buy	5,800 +300	+5%	+$17.6K	0.14%	90
2015 Q4	$361K	Hold	5,500	–	–	0.17%	58
2015 Q3	$311K	Sell	5,500 -2,000	-27%	-$130K	0.16%	65
2015 Q2	$443K	Hold	7,500	–	–	0.2%	66
2015 Q1	$467K	Hold	7,500	–	–	0.2%	69
2014 Q4	$431K	Sell	7,500 -700	-9%	-$39K	0.2%	78
2014 Q3	$441K	Sell	8,200 -3,000	-27%	-$159K	0.19%	77
2014 Q2	$587K	Sell	11,200 -2,000	-15%	-$102K	0.24%	76
2014 Q1	$697K	Sell	13,200 -7,500	-36%	-$347K	0.31%	66
2013 Q4	$830K	Sell	20,700 -15,950	-44%	-$628K	0.36%	56
2013 Q3	$1.39M	Sell	36,650 -9,600	-21%	-$374K	0.69%	43
2013 Q2	$1.81M	Buy	+46,250	New	+$1.8M	0.9%	37

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Shikiar Asset Management's TEVA Position: Q1 2017 in Review

Shikiar Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 6,045 shares — an estimated $219K sold.

Shikiar Asset Management first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $1.81M in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Shikiar Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Shikiar Asset Management sold 6,045 Teva Pharmaceuticals shares in Q1 2017, an estimated $219K.
Shikiar Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Shikiar Asset Management's Teva Pharmaceuticals position peaked at $1.81M in Q2 2013.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Shikiar Asset Management's 13F filing for Q1 2017, filed 28 Apr 2017.